VS-6766市場：市場規模、予測、新たな洞察-2032年

Verastem Oncologyが開発したVS-6766は、RAF/MEKクランプであり、MEKとARAF、BRAF、CRAFの不活性複合体を誘導し、RAS経路を最大限に阻害することで、より完全で持続的な抗腫瘍効果を生み出す可能性があります。VS-6766は、1分子でRAFとMEKの両方を阻害するので、抵抗性を克服し、最終的に腫瘍の成長と増殖を阻害するのに役立つ可能性が示唆されます。MEKのRAFリン酸化を阻害することで、VS-6766はpMEKを誘導しないという利点があり、ERKシグナルをより完全に阻害することで、VS-6766は治療活性を高める可能性があることが予備調査で示されています。VS-6766を単独で使用した場合、予備的データでは、難治性の婦人科がんにおいてRAS経路の変異を横断的に示すことが示されています。

VS-6766は、現在利用可能なMEKのみの阻害剤よりも忍容性が向上する可能性のある、新規の間欠的投与スケジュールと簡便な経口レジメンを提供し、VS-6766を複数の標的クラスの薬剤との併用療法に最適なパートナーにすることで、最も必要とされる患者により良い転帰をもたらす可能性があります。

今後数年間で、卵巣がんの市場シナリオは、世界中の広範な調査と医療支出の増加により変化します。各社は、病状を治療/改善するための新たなアプローチに焦点を当てた治療法を開発し、課題を評価し、VS-6766の優位性に影響を与える可能性のある機会を模索しています。VS-6766に対して、卵巣がんを対象とした他の新興製品が厳しい市場競争をもたらすことが予想され、近い将来、後発の新興治療薬が上市されれば、市場に大きな影響を与えるとみられています。

当レポートでは、主要7ヶ国における卵巣がん治療薬のVS-6766市場について調査し、市場の概要とともに、競合情勢、2032年までの市場規模予測、および国別市場分析などを提供しています。

目次

第1章 レポートのイントロダクション

第2章 卵巣がんにおけるVS-6766の概要

• 製品の詳細
• 臨床開発
  • 臨床研究
  • 臨床試験情報
  • 安全性と有効性
• その他の開発活動
• 製品プロファイル

第3章 競合情勢（上市済み治療法）

第4章 競合情勢（後期段階の新興治療法）

第5章 VS-6766市場評価

• 卵巣がんにおけるVS-6766の市場見通し
• 主要7ヶ国分析
  • 主要7ヶ国の卵巣がんにおけるVS-6766の市場規模
• 国別市場分析
  • 米国
  • ドイツ
  • 英国

第6章 SWOT分析

第7章 アナリストの見解

第8章 付録

第9章 DelveInsightのサービス内容

第10章 免責事項

第11章 DelveInsightについて

第12章 レポート購入オプション

List of Tables

• Table 1: VS-6766, Clinical Trial Description, 2023
• Table 2: VS-6766, General Description
• Table 3: Competitive Landscape (Marketed Therapies)
• Table 4: Competitive Landscape (Late-stage Emerging Therapies)
• Table 5: VS-6766 Market Size in the 7MM, in USD million (2019-2032)
• Table 6: VS-6766 Market Size in the US, in USD million (2019-2032)
• Table 7: VS-6766 Market Size in Germany, in USD million (2019-2032)
• Table 8: VS-6766 Market Size in France, in USD million (2019-2032)
• Table 9: VS-6766 Market Size in Italy, in USD million (2019-2032)
• Table 10: VS-6766 Market Size in Spain, in USD million (2019-2032)
• Table 11: VS-6766 Market Size in the UK, in USD million (2019-2032)
• Table 12: VS-6766 Market Size in Japan, in USD million (2019-2032)

List of Figures

• Figure 1: VS-6766 Market Size in the 7MM, USD million (2019-2032)
• Figure 2: VS-6766 Market Size in the United States, USD million (2019-2032)
• Figure 3: VS-6766 Market Size in Germany, USD million (2019-2032)
• Figure 4: VS-6766 Market Size in France, USD million (2019-2032)
• Figure 5: VS-6766 Market Size in Italy, USD million (2019-2032)
• Figure 6: VS-6766 Market Size in Spain, USD million (2019-2032)
• Figure 7: VS-6766 Market Size in the United Kingdom, USD million (2019-2032)
• Figure 8: VS-6766 Market Size in Japan, USD million (2019-2032)

"VS-6766 Market Size, Forecast, and Emerging Insight - 2032" report provides comprehensive insights about VS-6766 for ovarian cancer in the seven major markets. A detailed picture of the VS-6766 for ovarian cancer in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the VS-6766 for ovarian cancer. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the VS-6766 market forecast analysis for ovarian cancer in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in ovarian cancer.

Drug Summary:

VS-6766, developed by Verastem Oncology, is an RAF/MEK clamp that induces inactive complexes of MEK with ARAF, BRAF, and CRAF, potentially creating a more complete and durable antitumor response through maximal RAS pathway inhibition. VS-6766 blocks both RAF and MEK in a single molecule, suggesting it may help overcome resistance and ultimately block tumor growth and proliferation. By inhibiting RAF phosphorylation of MEK, VS-6766 has the advantage of not inducing pMEK, and by inhibiting ERK signaling more completely, preliminary research indicates VS-6766 may confer enhanced therapeutic activity. When used alone, preliminary data show that VS-6766 demonstrates across RAS pathway mutations in refractory gynecologic cancers.

VS-6766 offers a novel intermittent dosing schedule and convenient oral regimen with the possibility of better tolerability than currently available MEK-only inhibitors, which makes VS-6766 an optimal partner for combination therapy with agents from multiple target classes that may deliver better patient outcomes where they are needed most.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the VS-6766 description, mechanism of action, dosage and administration, research and development activities in ovarian cancer.
• Elaborated details on VS-6766 regulatory milestones and other development activities have been provided in this report.
• The report also highlights the VS-6766 research and development activities in ovarian cancer across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around VS-6766.
• The report contains forecasted sales of VS-6766 for ovarian cancer till 2032.
• Comprehensive coverage of the late-stage emerging therapies for ovarian cancer.
• The report also features the SWOT analysis with analyst views for VS-6766 in ovarian cancer.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

VS-6766 Analytical Perspective by DelveInsight

• In-depth VS-6766 Market Assessment

This report provides a detailed market assessment of VS-6766 for ovarian cancer in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2027 to 2032.

• VS-6766 Clinical Assessment

The report provides the clinical trials information of VS-6766 for ovarian cancer covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for ovarian cancer is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence VS-6766 dominance.
• Other emerging products for ovarian cancer are expected to give tough market competition to VS-6766 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of VS-6766 in ovarian cancer.
• Our in-depth analysis of the forecasted sales data of VS-6766 from 2027 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the VS-6766 in ovarian cancer.

Key Questions:

• What is the product type, route of administration and mechanism of action of VS-6766?
• What is the clinical trial status of the study related to VS-6766 in ovarian cancer and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the VS-6766 development?
• What are the key designations that have been granted to VS-6766 for ovarian cancer?
• What is the forecasted market scenario of VS-6766 for ovarian cancer?
• What are the forecasted sales of VS-6766 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to VS-6766 for ovarian cancer?
• Which are the late-stage emerging therapies under development for the treatment of ovarian cancer?

Table of Contents

1. Report Introduction

2. VS-6766 Overview in ovarian cancer

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Other Developmental Activities
• 2.4. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. VS-6766 Market Assessment

• 5.1. Market Outlook of VS-6766 in ovarian cancer
• 5.2. 7MM Analysis
  • 5.2.1. Market Size of VS-6766 in the 7MM for ovarian cancer
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of VS-6766 in the United States for ovarian cancer
  • 5.3.2. Market Size of VS-6766 in Germany for ovarian cancer
  • 5.3.3. Market Size of VS-6766 in France for ovarian cancer
  • 5.3.4. Market Size of VS-6766 in Italy for ovarian cancer
  • 5.3.5. Market Size of VS-6766 in Spain for ovarian cancer
  • 5.3.6. Market Size of VS-6766 in the United Kingdom for ovarian cancer
  • 5.3.7. Market Size of VS-6766 in Japan for ovarian cancer

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options